Upstream Bio highlights Phase 3 plan for verekitug in severe asthma, CRSwNP with quarterly at-home dosing
UPB•Phase 3 plans and quarterly dosing
-
Upstream Bio outlined Phase 3 plans for verekitug in severe asthma and CRSwNP, targeting a single 400 mg quarterly at-home injection.
-
Phase 2 CRSwNP VIBRANT met its primary endpoint, with a -1.8 nasal polyp score treatment difference versus placebo (p<0.0001).
-
VIBRANT also showed a -0.8 nasal congestion score difference (p=0.0003) and a 76% reduction in surgery or steroid need (p=0.03).
-
Phase 2 severe asthma VALIANT reported a 56% reduction in annualized exacerbation rate (p<0.0003), with 122 mL FEV1 improvement.
-
Enrollment completed in the Phase 2 COPD VENTURE trial, with data expected in H2 2027; existing capital expected to fund operations through 2027.
